Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, Bank of America Analyst Says

Vera Therapeutics (NASDAQ:VERA) had its target price boosted by stock analysts at Bank of America from $48.00 to $66.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective points to a potential upside of 28.86% from the stock’s current price.

Other research analysts have also recently issued reports about the company. Evercore ISI boosted their target price on Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. TD Cowen lifted their target price on shares of Vera Therapeutics from $60.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Wedbush lifted their price target on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. Finally, The Goldman Sachs Group upped their price target on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $74.83.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $51.22 on Friday. The company has a market capitalization of $3.27 billion, a P/E ratio of -12.84 and a beta of 1.21. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $51.72. The business’s 50 day moving average is $33.89 and its two-hundred day moving average is $27.28. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period in the prior year, the firm posted ($0.85) earnings per share. Analysts expect that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, SVP Joseph R. Young sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total transaction of $435,900.00. Following the sale, the senior vice president directly owned 47,839 shares in the company, valued at approximately $1,390,201.34. The trade was a 23.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patrick G. Enright purchased 5,882 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $42.50 per share, with a total value of $249,985.00. Following the transaction, the director directly owned 5,882 shares in the company, valued at $249,985. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in shares of Vera Therapeutics in the second quarter valued at about $51,000. Quarry LP grew its stake in shares of Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $60,000 after purchasing an additional 500 shares during the period. AlphaQuest LLC increased its holdings in shares of Vera Therapeutics by 404.7% in the first quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock worth $96,000 after acquiring an additional 3,213 shares in the last quarter. Virtus Investment Advisers LLC raised its stake in shares of Vera Therapeutics by 14.8% in the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after purchasing an additional 539 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after purchasing an additional 2,757 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.